Kazia CEO to Present at Guggenheim Healthcare Conference Nov. 9
SYDNEY – October 29, 2026 -- Kazia Therapeutics (NASDAQ: KZIA) will put its CEO and its head of corporate strategy in front of investors at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9, 2026, at 8:30 a.m. EST.
Fireside chat features CEO John Friend and strategy head Jeffrey Kraws
John Friend, MD, Chief Executive Officer, and Jeffrey Kraws, Head of Corporate Strategy & Development, will take part in a fireside chat on the conference's opening day. The conference runs November 9 to 11, 2026, in Boston, Massachusetts. A live webcast of the session will be available.
Paxalisib carries multiple FDA designations across brain tumor indications
Kazia's lead asset, paxalisib, is an investigational oral, brain-penetrant dual PI3K/mTOR inhibitor. It is in development for central nervous system cancers, advanced breast cancer and colorectal cancer. In the U.S., it holds the following FDA designations: